GLP-1 drugs are not dosed on one scale: 2.4 mg is the full maintenance dose of semaglutide, but 2.5 mg is only the starting dose of tirzepatide, and liraglutide is injected every day instead of every week. That is why a GLP-1 dosage chart has to be read drug by drug. Below: start doses, steps and maintenance doses for the main GLP-1 drugs side by side, what each achieved in its main trial, and how many syringe units those doses are.
Open the calculators → semaglutide, tirzepatide, retatrutide and more, for any vial.
GLP-1 dosage chart: all drugs side by side
| Drug | How often | Start | Steps | Maintenance | Average weight loss in main trial | Status (US) |
|---|---|---|---|---|---|---|
| Semaglutide (Wegovy) | weekly | 0.25 mg | every 4 weeks: 0.5 → 1 → 1.7 → 2.4 mg | 1.7 or 2.4 mg; 7.2 mg (Wegovy HD) | −14.9% (2.4 mg, 68 wk); −18.7% (7.2 mg, 72 wk) | Approved |
| Tirzepatide (Zepbound) | weekly | 2.5 mg | +2.5 mg after at least 4 weeks | 5, 10 or 15 mg | −20.9% (15 mg, 72 wk) | Approved |
| Liraglutide (Saxenda) | daily | 0.6 mg | +0.6 mg every week | 3 mg | −8.0% (3 mg, 56 wk) | Approved, generic |
| Retatrutide | weekly | 2 mg | every 4 weeks: 4 → 6 → 9 → 12 mg | 4, 9 or 12 mg | −28.3% (12 mg, 80 wk)* | Not approved; filing Q1 2027 |
| Mazdutide | weekly | 2 mg | +2 mg every 4 weeks | 4 or 6 mg | −14.8% (6 mg, 48 wk) | Approved in China only |
| Survodutide | weekly | low, gradual | gradual over several weeks | 3.6 or 6 mg | up to −16.6% (76 wk)* | Not approved |
| CagriSema (cagrilintide + semaglutide) | weekly | — | stepwise | 2.4 + 2.4 mg | −20.4% (68 wk) | Not approved |
Weight loss is the average in each drug’s main Phase 3 trial versus placebo, and trials differ in length and population, so the numbers are a rough guide, not a head-to-head ranking. * Average if people stayed on treatment; counting everyone, retatrutide 12 mg gave −25.0%. Wegovy HD (7.2 mg) is approved in the US for people who have tolerated 2.4 mg for at least 4 weeks.
Why the same mg is not the same dose
Each molecule has its own strength per milligram. Switching from semaglutide 2.4 mg to tirzepatide does not mean injecting 2.4 mg of tirzepatide; people who switch normally restart from the new drug’s own schedule, as decided by their prescriber. The same goes for mixing up liraglutide and semaglutide: 3 mg of liraglutide a day is a normal dose, while 3 mg of semaglutide a week is above the standard 2.4 mg maintenance dose.
Maintenance doses in syringe units
Rule: units = mg ÷ mg/mL × 100 on a U-100 insulin syringe. Common compounded and research strengths:
| Maintenance dose | Units at 2.5 mg/mL | Units at 5 mg/mL | Units at 10 mg/mL | Units at 20 mg/mL |
|---|---|---|---|---|
| Semaglutide 2.4 mg | 96 | 48 | 24 | 12 |
| Semaglutide HD 7.2 mg | 288 ** | 144 ** | 72 | 36 |
| Liraglutide (daily) 3 mg | 120 ** | 60 | 30 | 15 |
| Tirzepatide 5 mg | 200 ** | 100 | 50 | 25 |
| Tirzepatide 10 mg | 400 ** | 200 ** | 100 | 50 |
| Tirzepatide 15 mg | 600 ** | 300 ** | 150 ** | 75 |
| Retatrutide 4 mg | 160 ** | 80 | 40 | 20 |
| Retatrutide 12 mg | 480 ** | 240 ** | 120 ** | 60 |
| Mazdutide 6 mg | 240 ** | 120 ** | 60 | 30 |
| Survodutide 3.6 mg | 144 ** | 72 | 36 | 18 |
** More than one 100-unit (1 mL) syringe. Branded pens (Wegovy, Zepbound, Saxenda) are dialled or fixed in mg and need no units; this table is for vials.
What the chart does not tell you
- Faster is not better. Every label and trial raised doses in steps, usually 4 weeks apart, because stomach side effects are worst right after an increase.
- Higher is not required. Lower maintenance doses (semaglutide 1.7 mg, tirzepatide 5 or 10 mg) are approved options, not failures.
- Unapproved means unverified. For retatrutide, survodutide and CagriSema the doses come from trials of the companies’ own products; vials sold online are a different thing.
Detailed charts in units: semaglutide, tirzepatide, retatrutide, and microdosing semaglutide.
Drug-specific water guides: how much BAC water for tirzepatide and for 10 mg retatrutide.
Prefer a pill? Orforglipron (Foundayo) is a once-daily GLP-1 tablet with no injections and no fasting rules. Our orforglipron dosage chart lists all six tablet strengths, the step-up schedule and how trial doses such as 36 mg convert to today’s tablets.
Sources
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989–1002.
- HCPLive. FDA approves higher dose semaglutide (Wegovy HD) injection 7.2 mg for obesity (March 19, 2026).
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205–216; dosing: Drugs.com tirzepatide monograph.
- Drugs.com. Saxenda (liraglutide) prescribing information; SCALE trial, N Engl J Med 2015.
- Eli Lilly via BioSpace. Retatrutide TRIUMPH-1 Phase 3 results (May 21, 2026).
- Ji L, et al. Once-weekly mazdutide in Chinese adults with obesity or overweight (GLORY-1). N Engl J Med 2025.
- SYNCHRONIZE-1 (survodutide), ACC journal scan (June 2026).
- Garvey WT, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). N Engl J Med 2025.

